Journal
VIRCHOWS ARCHIV
Volume 471, Issue 6, Pages 761-767Publisher
SPRINGER
DOI: 10.1007/s00428-017-2164-5
Keywords
PUNLMP; TERT; FGRF3; TP53; PIK3CA; Early detection; Bladder neoplasm
Categories
Funding
- Johns Hopkins Greenberg Bladder Cancer Institute
- Virginia and D.K. Ludwig Fund for Cancer Research
- Commonwealth Fund
- Conrad R. Hilton Foundation
- Sol Goldman Sequencing Facility at Johns Hopkins
Ask authors/readers for more resources
Our group and others have previously demonstrated the presence of TERT promoter mutations (TERT-mut) in 60-80% of urothelial carcinomas and some of their histologic variants. Five other genes have been frequently implicated in bladder cancer: FGRF3, TP53, PIK3CA, HRAS, and CDKN2A. In the current study, we sought to determine the prevalence of mutations in TERT and these five other genes in de novo papillary urothelial neoplasms of low malignant potential (PUNLMP) of the urinary bladder. A retrospective search of our archives for PUNLMP was performed and 30 de novo cases were identified and included in the study. We found mutations in TERT (TERT-mut) and FGFR3 (FGFR3-mut) to be the most common alterations in the cohort (63 and 60%, respectively). The majority of the TERT-mut-positive tumors (84%) had a g. 1295228C > T alteration with the remaining tumors demonstrating g. 1295250C > T. Approximately one fourth of tumors had TP53 mutations. These findings support the potential utility of a uniform genetic mutation panel to detect bladder cancers of various subtypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available